ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell)…
I'm disappointed to see $IBRX not hold a Q3 earnings call. Communication with shareholders is important.
It's not widely understood that my portfolio is a small collection of massively asymmetric bets If just one works out like I expect it to, like $AMD, the portfolio obliterates the index It's very early days for the ALC portfolio, with $HIMS, $DUOL, $IBRX and $NAUT at infancy…
Companies with no actual competition: 1. $PLTR 2. $DUOL 3. $HIMS 4. $TSLA 5. $SPOT 6. $NAUT 7. $IBRX
Learn the mental framework behind my $AMD, $PLTR, $NAUT and $IBRX picks https://t.co/XnYjPjtXxK
THE FINX MARKET GUIDE FOR BEGINNERS A watchlist by sector and theme. Neoclouds & AI Compute $NBIS $IREN $CRWV Photonics & AI Connectivity $AAOI $CRDO $LITE $COHR $ALAB Space $ASTS $RKLB $SPCX $FLY $VOYG Biotech & Life Sciences $NAUT $ABCL $IBRX Robotics & Automation $OUST…
4 analysts rate IBRX Buy on consensus.
Consensus price target: $14.25 (+136.71% upside from $6.02)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Simon Barry J. director | Oct 5, 2026 | Sale | 25,000 | $268.76K |
| Selecky Christobel director | Jun 30, 2026 | Sale | 1,000 | $9K |
| Selecky Christobel director | Jun 29, 2026 | Sale | 95,722 | $862.22K |
| Simon Barry J. director | Jun 24, 2026 | Sale | 25,000 | $196.91K |
| Simon Barry J. director | Jun 4, 2026 | Sale | 23,033 | $165.31K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $113.29M | +668.31% | $-351.4M |
| 2024 | $14.75M | +2270.58% | $-413.56M |
| 2023 | $622K | +159.17% | $-583.2M |
Stock data for IBRX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics